Cargando…
Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX
BACKGROUND: Thrombotic events are reduced with cangrelor, an intravenous P2Y(12) inhibitor. We sought to characterize the timing, number, and type of early events (within 2 hours of randomization) in CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Su...
Autores principales: | Cavender, Matthew A., Harrington, Robert A., Stone, Gregg W., Steg, Ph. Gabriel, Gibson, C. Michael, Hamm, Christian W., Price, Matthew J., Lopes, Renato D., Leonardi, Sergio, Deliargyris, Efthymios N., Prats, Jayne, Mahaffey, Kenneth W., White, Harvey D., Bhatt, Deepak L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8765214/ https://www.ncbi.nlm.nih.gov/pubmed/34915723 http://dx.doi.org/10.1161/CIRCINTERVENTIONS.120.010390 |
Ejemplares similares
-
Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition)
por: Cavender, Matthew A., et al.
Publicado: (2016) -
The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX
por: Gutierrez, J. Antonio, et al.
Publicado: (2016) -
Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention: Insights From the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) Trial
por: O’Donoghue, Michelle L., et al.
Publicado: (2016) -
Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial
por: Vaduganathan, Muthiah, et al.
Publicado: (2016) -
The efficacy and safety of cangrelor in single vessel vs multivessel percutaneous coronary intervention: Insights from CHAMPION PHOENIX
por: Yong, Celina M., et al.
Publicado: (2019)